FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)

View source ↗

Summary

FDA approved a supplemental application for KEPPRA XR (levetiracetam), the extended-release formulation, submitted by UCB, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Generalized Tonic-clonic Seizures
• Partial-onset Seizures

Drugs mentioned

• KEPPRA XR (levetiracetam)

Snippet

SUPPL AP for KEPPRA XR (LEVETIRACETAM)